Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2014; 6(6): 170-176
Published online Jun 15, 2014. doi: 10.4251/wjgo.v6.i6.170
Published online Jun 15, 2014. doi: 10.4251/wjgo.v6.i6.170
Monoclonal antibodies that target the immunogenic proteins expressed in colorectal cancer
Myron Arlen, Gene Coppa, Jim Crawford, Ernesto Molmenti, Department of Surgery, Division of Surgical Oncology and the Dept. of Pathology, North Shore University Hospital, Manhasset, NY 11030, United States
Philip Arlen, XuePing Wang, Olga Saric, Alex Dubeykovskiy, Manhasset NY and Precision Biologics, Great Neck, NY 11021, United States
Author contributions: All the authors contributed to this paper.
Correspondence to: Myron Arlen, MD, Manhasset NY and Precision Biologics, 445 Northern Blvd, Great Neck, NY 11021, United States. marlenmd@msn.com
Telephone: +1-516-4879454 Fax: +1-516-4872745
Received: November 9, 2013
Revised: May 1, 2014
Accepted: May 14, 2014
Published online: June 15, 2014
Processing time: 223 Days and 3.7 Hours
Revised: May 1, 2014
Accepted: May 14, 2014
Published online: June 15, 2014
Processing time: 223 Days and 3.7 Hours
Core Tip
Core tip: The ideal monoclonal antibody to be employed in cancer management is one targeting an immunogenic protein expressed in a specific cancer system. Those presently employed in cancer management, target a growth factor or carbohydrate antigen seen in both cancer and normal tissue. Their value as such is limited. The monoclonals described herein are directed against colon cancer tumor associated antigen and have value in both diagnostic and therapeutic uses for controlling this disease.